Ennaid Therapeutics advances work on Zika virus in wake of crisis

15 February 2016

Privately-held Georgia, USA-based Ennaid Therapeutics, says it is developing therapeutic cures to help the millions of people worldwide when infected with the mosquito-borne disease, Zika Virus, now named a global public health emergency by the World Health Organization and the Centers for Disease Prevention and Control (CDC).

The global health community is urging caution and care in response to Zika's explosive spread and is calling for rapidly stepped up efforts by researchers to find therapeutics and vaccines for those who contract it.

For years, Ennaid Therapeutics has been committed to developing cures for mosquito-borne diseases, including Dengue, Chikungunya and Zika viruses – and is now advancing its work on Zika to address the urgent global need.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK